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Despite recent advances in the development of new cancer thera-
pies, the treatment options for glioma remain limited, and the
survival rate of patients has changed little over the past three dec-
ades. Here, we show that 2-hydroxyoleic acid (2OHOA) induces
differentiation and autophagy of human glioma cells. Compared to
the current reference drug for this condition, temozolomide (TMZ),
2OHOA combated glioma more efficiently and, unlike TMZ, tumor
relapse was not observed following 2OHOA treatment. The novel
mechanism of action of 2OHOA is associated with important
changes in membrane-lipid composition, primarily a recovery of
sphingomyelin (SM) levels, which is markedly low in glioma cells
before treatment. Parallel to membrane-lipid regulation, treatment
with 2OHOA induced a dramatic translocation of Ras from the
membrane to the cytoplasm, which inhibited the MAP kinase path-
way, reduced activity of the PI3K/Akt pathway, and downregulated
Cyclin D-CDK4/6 proteins followed by hypophosphorylation of
the retinoblastoma protein (RB). These regulatory effects were as-
sociated with induction of glioma cell differentiation into mature
glial cells followed by autophagic cell death. Given its high efficacy,
low toxicity, ease of oral administration, and good distribution
to the brain, 2OHOA constitutes a new and potentially valuable
therapeutic tool for glioma patients.
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Cancer cells of undifferentiated phenotype (e.g., glioma) havea poor prognosis and limited treatment options. Primary
brain tumors, of which glioma is the most common, are generally
associated with very high rates of mortality (ca. 90%), being the
median survival of patients about 1 y (1, 2). Chemotherapy pro-
vides only modest benefits to radiotherapy and surgery being the
alkylating agent temozolomide (TMZ) the reference drug; how-
ever, tumor relapse is usually observed, and TMZ only increases
the patients’ life expectancy about 2.5 m (from 12.1 to 14.6 m:
ref. 3). The present study was designed to investigate the efficacy
of 2OHOA against glioma and its molecular mechanisms of
action. 2OHOA exhibited a greater efficacy than TMZ in the
treatment of glioma, and there was no relapse after long-term
treatment with 2OHOA. This efficacy and lack of toxicity at ther-
apeutic doses has been acknowledged recently by the European
Medicines Agency (EMA) to designate 2OHOA orphan drug for
the treatment of glioma. In previous studies, we showed that this
compound induces cell cycle arrest of lung cancer cells (4–6).
Here, we showed that 2OHOA reversed the altered lipid profile
of glioma cells and how this modification regulated cell signaling
to induce autophagy specifically in glioma but not normal cells.
Moreover, in the present study we demonstrated that the
changes induced by 2OHOA were specific to cancer cells with no
significant effects observed in normal cells and no adverse effects
in treated animals, features not shared by most anticancer drugs.
The efficacy of this compound in the absence of any relevant
toxicity indicates that 2OHOA may be a useful and innovative
therapeutic tool to treat glioma.
Results
Efficacy of 2OHOA and TMZ Against Glioma. The efficacy of 2OHOA
against glioma was tested in the human glioma cell lines SF767,
U118, A172, and T98G. In these lines, 2OHOA induced a time
and concentration dependent inhibition of cell growth (Fig. 1A
and Fig. S1A). Likewise, TMZ induced inhibition of human
SF767 glioma cell growth, but it failed to kill all the cancer cells
in culture exhibiting a lower efficacy in this model of human glio-
ma than 2OHOA.
In a xenograft model of human glioma (SF767 cells), 2OHOA
was also more potent than TMZ (Fig. 1B). This effect was dose
dependent being the sodium salt more potent than other forms
of 2OHOA (Fig. S1B); therefore, it was used throughout this
work. In this context, the combined treatment with both was more
efficient than either alone possibly because their different modes
of action (600 mg∕kg 2OHOA and/or 80 mg∕kg TMZ, p.o.,
daily, 50 d: Fig. 1B). To determine possible tumor relapse after
treatment, both compounds were assessed for a further 21 d after
60 d treatments. Following TMZ treatment, the tumors derived
from human glioma SF767 cells again grew in an aggressive man-
ner (Fig. 1B). Similar results have been reported in patients with
glioma in whom TMZ treatment only increases median survival
by 10 wk (3, 7, 8). In contrast, tumor relapse was not observed
after 2OHOA treatment (Fig. 1B). Using an orthotopic model
of human glioma, oral administration of 2OHOA completely
eliminated glioma cell tumors in the brain of three mice and,
in the other two, only a few SF767 cells remained (Fig. 1C and
Fig. S1C). In this context, HuNuþ (i.e., human glioma) cells were
in the vicinity of the ventricle with some labeling on the choroid
plexus. In animals treated with TMZ, a reduction of the tumor
size was also observed; though, the size of tumors and their
immunoreactivity were greater than in animals treated with
2OHOA (Fig. 1 and Fig. S1).
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2OHOA Regulates GliomaMembrane-Lipid Composition and Structure.
2OHOA is a synthetic fatty acid that readily binds to the plasma
membrane and regulates its lipid structure (4, 9). It induces
important changes in the membrane structure that favor the
binding of certain proteins like protein kinase Cα (PKCα: 4, 9).
2OHOA was detected in SF767 cell membranes as a free fatty
acid (ca. 7%) or incorporated in phospholipids (ca. 30%), con-
stituting a major membrane fatty acid upon treatment. In addi-
tion, significant alterations in the levels of various membrane
lipids were observed after 2OHOA treatment including marked
increases in SM (ca. 2-fold: Fig. 2) and 1,2-diacylglycerol (DAG,
from 2.05 0.17 in untreated cells to 3.02 0.11 nmole∕mg
protein in 2OHOA-treated cells) and marked decreases in phos-
phatidylethanolamine (PE) mass (Fig. 2). No such changes were
observed following 2OHOA treatment of normal (MRC-5) cells
(Fig. 2 and Fig. S2) that already exhibit high basal levels of SM.
The increase in DAG and the presence of 2OHOA itself favors
the cytosol to membrane translocation and activation of PKCα
(4, 10) that is associated with knockdown of E2F-1 and DHFR
(5, 6). The increase in membrane 2OHOA was likely associated
with short-term (10 min) Ras release from the membrane and the
subsequent inhibition of the ERK pathway, and changes in SM
and PE could be related the long-term Ras translocation (Fig. 3
and Fig. S3).
2OHOA Inhibits the EGFR/Ras/MAP Kinase and PI3K/Akt Pathways in
Glioma cells.The EGFR/Ras/MAP kinase and PI3K/Akt pathways
are usually hyperactive and cause proliferation and loss of differ-
entiation in glial cells (11–14). Treatment with 2OHOA, which
induced changes in the membrane-lipid composition of glioma
cells, caused translocation of Ras from the plasma membrane to
the cytoplasm (the perimembranal content of Ras determined by
confocal microscopy changed from 87 6% to 6 3% in the ab-
sence or presence of 2OHOA); but, it did not significantly change
the total cellular Ras content (98.6 4.4% and 94.7 6.2% in
control and 2OHOA-treated cells, as determined by immunoblot-
ting: Fig. S4). Ras propagates incoming messages from mem-
brane growth factor receptors (e.g., EGFR) to downstream
proteins such as Raf at defined ld lipid microdomains in the plas-
ma membrane (15, 16). As such, its translocation to the cytoplasm
greatly affected the proliferative Ras/MAPK signaling, which is
frequently overactive in cancer cells and responsible for their loss
of differentiation (17, 18). Indeed, a significant reduction in the
levels of phospho-EGFR and phosphorylated (i.e., active) cRaf,
MEK and MAP kinases (ERK1 and ERK2) was observed in vitro
(SF767 cells) and in vivo (tumors) after 2OHOA treatments
(Fig. 3, and Figs. S3 and S4). No significant changes in the levels
of total Raf, MEK, or ERK were observed (Fig. S4). The PI3K/
Akt signaling pathway is involved in cell survival and growth in
Fig. 1. Efficacy of 2OHOA against human glioma (SF767) cells and tumors. (A) Time and concentration dependent inhibition of human glioma (SF767) cell
growth by 2OHOA (left), TMZ (center), and their compared efficacy at 96 h (right, N ¼ 6–8). (B) Effects of vehicle (control), 2OHOA, TMZ or both against SF767-
derived tumor growth in mice during 50 d treatments (left, N ¼ 20), 60-d treatments (center, N ¼ 15), and tumor volumes during 3 wk following 60 d treat-
ments (right). ***P < 0.001 with respect to control; #, P < 0.05, ###, P < 0.001 with respect to TMZ alone; §§, P < 0.01 with respect to 2OHOA or TMZ alone.
(C) Effects of vehicle (1, 2), TMZ (3, 4), and 2OHOA (5, 6) on orthotopic human glioma growth (SF767 cells) in the brain of nude mice after 42 d treatments
(N ¼ 5). Additional pictures are shown in Fig. S1. In all cases, the doses were 600 mg∕kg for 2OHOA and 80 mg∕kg for TMZ (p.o., daily). Scale bars ¼ 200 μm
(1, 3, 5) and 50 μm (2, 4, 6).
Fig. 2. 2OHOA (72 h, 200 μM) induces changes in SF767 membrane-lipid
composition. Upper panel, Levels of the major phospholipid classes before
(black bars) and after (gray bars) 2OHOA treatment: PC, phosphatidylcholine;
PE, phosphatidylethanolamine; SM, sphingomyelin; PS, phosphatidylserine;
PI, phosphatidylinositol; LPC, lyso-phosphatidylcholine. Lower panel, effects
of 2OHOA (72 h, 200 μM) on SM levels in normal (MRC5) and glioma (SF767)
cells before (black) and after (gray) treatment (N ¼ 6–8).
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cooperation with the Ras/MAPK pathway in cancer cells (17).
Following 2OHOA treatment, we observed a significant reduc-
tion in Akt phosphorylation indicating that this protein is prefer-
entially inactive (Fig. 3).
2OHOA Induces Cell Cycle Arrest in Human Glioma Cells. Cell cycle
arrest has been shown to occur in response to PKC activation
in various cancer cell types (4–6, 19, 20). In human glioma cells,
we have seen that 2OHOA induced a rapid (minutes) and sus-
tained (over 24 h) activation (translocation to membrane) of
PKC that caused overexpression of p21Cip1 and a simultaneous
increase of p27Kip1 (Fig. S5). These potent CDK inhibitors
(CDKIs, ref. 21) are frequently downregulated in gliomas, and
their rise induced decreases of Cyclin D1, Cyclin D3, and
CDK4 and CDK6 that caused RB hypophosphorylation, E2F-1
downregulaiton and DHFR knockdown (Fig. S5) followed by cell
cycle arrest in G0∕1 of glioma cells. No significant changes in the
levels of these proteins were seen in MRC-5 cells (immunoreac-
tivities for these proteins were 91–112% for all these proteins
being P > 0.05 always).
2OHOA Induces Human Glioma Cell Differentiation. In addition to
their increased proliferation, glioma cells lose many molecular
and morphological features of differentiated glial cells such as
the typical stellar shape and the expression of glutamine synthe-
tase (GS) and glial fibrillary acidic protein (GFAP; 22, 23). It has
been proposed that inducing differentiation may be a suitable
approach to treat cancer given its potential specificity and low
level of toxicity (24). In this context, treatment with 2OHOA in-
duced a marked differentiation of glioma cells resulting in the
recovery of the stellar morphology of mature astrocytes and
the expression (in vitro and in vivo) of the glial differentiation
markers GFAP and GS, in SF767 cells (Fig. 4). Because the final
effect of 2OHOAwas induction of autophagy, it could be feasible
Fig. 4. 2OHOA induces glioma cell differentiation in vitro and in vivo. Top,
phase contrast micrographs of SF767 and U118 (human glioma) cells main-
tained in the presence or absence (control) of 2OHOA for 72 h (Left,
200 μM, 200x magnification). 2OHOA induced the expression of GFAP and
GS (right) in SF767 cells as determined in immunoblots. Bottom, In vivo near
infrared detection of a fluorolabeled anti-GS antibody in nude mice with
SF767-derived tumors following treatment with the vehicle lone (control),
2OHOA and TMZ (Left, N ¼ 10 per group) and the corresponding quantifica-
tion (Right, GSNIR, mean SEM). GS was also determined ex vivo in these
animals using immunoblotting (GSIB). GFAP was also quantified by immuno-
cytochemistry (GFAPIC, Right).
Fig. 3. Effect of 2OHOA on theMAPK (ERK) and PI3K/Akt pathways in SF767
cells. Top: 2OHOA (150 μM) induces Ras (green fluorescence) translocation
from the membrane to the cytoplasm after incubations of 10 min (1) or
24 h (2). Ph. C.: phase contrast micrography. In confocal micrographies,
the red fluorescence corresponds to the membrane labeling as detected with
the raft marker Vybrant Alexa Fluor 594 (Molecular Probes). Effects of
2OHOA (0, 150, 200, and 250 μM) on the phosphorylation (i.e., activity) of
Raf (second panel), MEK and ERK1/2 (third panel), and EGF-stimulated Akt
and EGFR phosphorylation (150 μM, 12 h after a 15 min stimulation with
35 ng∕ml EGF; bottom panel). N ¼ 6–8 in all cases.
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that redifferentiation may lead to the initiation of death programs
in cancer cells, though this point requires further studies.
2OHOA Induces Glioma Cell Autophagy. 2OHOA treatment resulted
in the death of the majority of cells in tumors derived from SF767
cells (Fig. 5 and Fig. S6). Similarly, in cultured SF767 cells, long-
term (120 h) incubation with 2OHOA induced important mor-
phological alterations that were observed in semithin sections
(1.5 μm) by optical microscopy and thin (0.06–0.09 μm) sections
by electron microscopy (Fig. 5). Thus, optical microscopy images
revealed that untreated cells were oval in shape, with nuclei
containing multiple nucleoli distributed along the nuclear matrix
and few invaginations. In contrast, 2OHOA-treated cells (120 h,
300 μM) exhibited irregular morphology and were markedly
smaller. Their nuclei were also smaller and contained deep inva-
ginations whose depth was concentration dependent (Fig. 5).
Notably, 2OHOA induced the appearance of lipid droplets and
dense bodies, the latter scattered throughout the cytoplasm and
some exhibiting morphological characteristics of autophago-
somes (Fig. 5). At low and high 2OHOA concentrations, a loss
of ER cisternae was observed in the cytoplasm consistent with
the autophagic process (Fig. 5).
In turn, the unspecific ER stress inducer palmitic acid caused
similar autophagosome synthesis induction in SF767 and MRC-5
cells (Fig. S6B). Finally, the expression of the autophagosome
proteins LC3B and ATG5 increased significantly in a time and
concentration dependent manner in SF767 cells (Fig. 5).
Discussion
In this study, the efficacy of the synthetic fatty acid 2OHOA in the
treatment of glioma was demonstrated, and its mode of action
Fig. 5. (A) Electron microscopy of SF767 cells maintained for 120 h in the presence or absence (control, panels 1, 5, 8, and 10) of 2OHOA (100 μM: panel 2;
200 μM: panels 3, 6, and 7; 300 μM: panels 4, 9 and 11). Arrows in panel 6 correspond to SF767 fragments. In panel 7, V corresponds to lipid vesicles and A
accounts for autophagosomes. The nuclei of SF767 cells cultured in the presence (panel 9) or absence (panel 8) of 2OHOA are shown, and the white arrows
correspond to nuclear invaginations (bar ¼ 2.5μm). 2OHOA treatment caused loss of rough endoplasmic reticulum cisternae in 2OHOA-treated cells (panel 11)
compared with control cells (panel 10, arrows show cisternae; bar ¼ 0.5 μm). N ¼ 300 for each concentration and time used. (B) Upper panels, optical micro-
scope photographs (1.5 μm semithin sections) showing SF767 cells treated for 120 h with vehicle (control) or 2OHOA (300 μM). Bottom panels, Fluorescence of
lysosome/autophagosome labeled with Lysosensor in SF767 cells in the presence or absence (left) of 2OHOA (150 μM for 48 h, right). N ¼ 400 cells from five
independent experiments. The relative fluorescence was quantified using the Image J 1.38x software, and data are indicated in the Results section. (C) Effect of
2OHOA (150 μM and 200 μM) at different times (24–96 h) on the markers of autophagy, LC3B (upper panel) and Atg5 (lower panel).
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described, driving glioma-to-glial cell differentiation that was
followed by autophagy through the specific inhibition of the Ras-
MAPK, Cyclin/CDK-DHFR, and PI3K-Akt pathways. 2OHOA is
more efficient drug against human glioma than TMZ, the current
reference drug to treat this condition. Unlike TMZ, no tumor
relapse was observed following 2OHOA treatment (Fig. 1). Its
low toxicity (IC50 > 5;000 μM, in normal MRC5 cells, and mini-
mum lethal dose >3;000 mg∕kg in rats) is unusual for anticancer
drugs further supporting the specificity of 2OHOA and its use as
differentiation therapy agent to treat cancer (24). Based on these
facts, the EMA has acknowledged the potential significant ben-
efit of 2OHOA and has recently designated this molecule an or-
phan drug for the treatment of glioma.
The plasma membrane contains thousands of different lipids
that form various types of membrane microdomains that can be
differentially and specifically regulated by drugs targeting the li-
pid bilayer. Thus, membrane-lipid therapy aims at the specific
regulation of certain membrane-lipid structures to treat cancer
and other human pathologies (25). In this context, very low levels
of SM were found in human glioma (SF767) cells when compared
with normal (MRC-5) cells, a characteristic common to all the
cancer cell lines that we have studied to date (leukemia, lung can-
cer, and other glioma cells; ref. 26). In SF767 cells, 2OHOA treat-
ments induced restoration of SM to levels similar to those
observed in nontumor cells (Fig. 2). This observation (along with
other results shown here) suggests that lower SM levels in cancer
cells could facilitate high Ras-MAPK activity to express the ma-
lignant phenotype. The bulky isoprenyl moiety of Ras proteins
can be anchored in membrane domains with high content of
PE whereas it is excluded from SM-rich domains where the dense
surface membrane packing prevents isoprenyl binding. Thus, Ras
translocation to the cytoplasm (Fig. 3) was probably caused by
changes in membrane lipids induced by 2OHOA, which could im-
pair productive interactions between EGFR and Ras and Ras and
Raf at the plasma membrane, and finally inactivate the MAPK
cascade (protein expression was not altered). In fact, tipifarnib
and other farnesyl transferase inhibitors exert their anticancer
effects impairing Ras binding to membranes by blocking Ras iso-
prenylation (27). Therefore, the presence of 2OHOA first and
the normalization of SM and PE levels, later induced changes
in the membrane-lipid structure that caused recovery of the lo-
calization and activity of relevant signaling proteins (Fig. 2, and
Figs. S2 and S3), which constitutes an alternative approach for
the treatment of cancer (28). In this context, the regulation of
SM levels by 2OHOA (via activation of sphingomyelin synthe-
tase, ref. 26) is crucial in its mechanism of action against glioma.
In line with these results, the addition of SM to culture medium
enhances gemcitabine-mediated pancreatic cancer cell death (29)
further indicating the relevance of this lipid in cancer cell survival.
On the other hand, 2OHOA treatments induced specific changes
in the levels of other membrane lipids (DAG, PE, and 2OHOA)
that contributed to remodel membrane microdomains and regu-
lated glioma cell signaling (30–32). These changes also facilitated
the membrane binding and activation of PKCα (4, 10, and Fig. S5)
that, itself, triggers inhibitory effects against cancer cell growth
(4, 19, 20, and Fig. 5).
The canonical signaling cassette made up of EGFR, Ras,
Raf, MEK, and ERK and/or the PI3K/Akt signaling pathway
are overactivated in most human gliomas as well as in other types
of cancer, and they often cooperate to induce malignant transfor-
mation of cancer cells (15, 17, 18, 33–36). In the present study, we
demonstrated that 2OHOA mediates the translocation of Ras
from the plasma membrane to the cytoplasm as well as the sub-
sequent inhibition of the MAP kinase (ERK, in vitro and in vivo)
PI3K/Akt and Cyclin/CDK pathways (Fig. 3 and Fig. S4). In glio-
ma cells, activation of the EGFR/Ras/Raf/ERK pathway blocks
differentiation and induces the dedifferentiation of glial cells
(11). Thus, inhibition of this signaling cascade constitutes a cen-
tral event in the glioma-to-glial cell differentiation induced by
2OHOA, and it is most likely involved in 2OHOA-mediated cell
cycle arrest and induction of autophagy.
2OHOA-induced PKC translocation to the membrane (and its
concomitant activation) is associated with overexpression of
the CDKI p21Cip1 (4) and possibly of p27Kip1 (Fig. S5), and with
β-catenin downregulation (4, 19, 20). 2OHOA-induced overex-
pression of CDKIs and inactivation of cyclin D-CDK4/6 com-
plexes (Fig. S5) is also associated with decreased Akt levels
and RB phosphorylation (4, 37) and, therefore, with lower cell
proliferation and reduced survival. Hypophosphorylation of RB
prevents its dissociation from E2F-1 inhibiting the expression and
activation of E2F-1, a pivotal transcription factor in cell cycle pro-
gression. These multiple regulatory effects probably contributed
to glioma cell differentiation via inhibition of the MAPK-pathway
as determined by the morphological (astroglial shape recovery)
and molecular (increased expression of GS and GFAP) changes
caused by 2OHOA, in vitro and in vivo.
We have shown in the present and previous studies (26) that
the plasma membrane of glioma and all other cancer cells studied
exhibit markedly low SM levels that appear to constitute a basic
requirement to express the malignant phenotype. In the present
study, we showed that 2OHOA induced recovery of SM levels
and it was associated with potent effects against glioma. This fact
suggests that remodeling of the membrane structure and compo-
sition would be upstream to the oncogenic action of Ras in cancer
cells. Furthermore, this anticancer effect was associated with a
dual-mode mechanism of action. On the one hand, the presence
of 2OHOA in membranes and the increase in DAG would induce
PKC translocation to membranes followed by CDKI overexpres-
sion and pRb hypophosphorylation (this work and refs. 4–6). On
the other hand, Ras translocation to the cytosol would cause
MAPK and Akt inactivation. These two pathways have been con-
sistently seen to be involved in the loss of differentiation, in-
creased proliferation, and survival of cancer cells so that their
regulation by 2OHOA is most likely responsible for the induction
of differentiation and autophagy observed upon treatment. In
any case, additional molecular events/mechanisms should not
be discarded. Indeed, we have recently seen that 2OHOA also
induces marked increases in the levels of nuclear SM (26). In this
context, nuclear phospholipids have been shown to participate in
nuclear signaling and could account for some of the cellular
effects induced by 2OHOA including glioma cell proliferation,
differentiation and death (38).
Autophagy is an alternative program of cell death that may
overcome the resistance of many cancers (e.g., glioma) to enter
the apoptotic program (39). In this context, we detected that
2OHOA-induced autophagy in SF767 cells (Fig. 5). Thus, there
were observed marked time and concentration dependent in-
creases in the levels of ATG5 and LC3B, both proteins fundamen-
tal for the formation of autophagosomes (40). The induction of
autophagy in glioma cells is triggered by RB hypophosphorylation
and p27kip1-mediated Akt inhibition (41) events induced by
2OHOA on these cells. In this context, the modifications in glio-
ma cells caused by 2OHOA resulted in profound morphological
changes, cell fragmentation, the release of cytosolic bodies con-
taining ER cisternae, and an increase in lysosomes/autophago-
somes, which is further evidence that autophagy is initiated.
The high extent of autophagy in glioma cells upon treatment
with 2OHOA specifically kills cancer but not nontumor cells and
supports a recent hypothesis suggesting that autophagy might be
used as a potential cancer therapy (42). The fact that autophagy
occurred after induction of differentiation in SF767 cells treated
with 2OHOA suggests that recovery of the features of mature
cells may cause a molecular conflict to cancer cells. In contrast,
neither autophagy nor the other molecular events here described
were induced by 2OHOA in normal cells. This mechanism of
action explains the extensive tumor cell death and lack of relapse
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in animals treated with 2OHOA. Thus, 2OHOA is a first-in-class
nontoxic membrane-lipid anticancer drug that activates sphingo-
myelin synthase and subsequently inhibits the MAPK and related
oncogenic pathways.
Methods
Cells were incubated in DMEM (SF767) or RPMI 1640 (U118, A172 and T98G)
in the presence of 10% FBS and antibiotics and in the presence or absence of
2OHOA or TMZ. Xenograft gliomas (subcutaneous and orthotopic) were
developed in immunosuppressed mice by inoculation of SF767 cells. The data
are expressed as the mean SEM values from 6–8 independent experiments
or the number of animals indicated. Statistical significance was indicated:
*, P < 0.05, **, P < 0.01, and ***, P < 0.001. Further details of the experi-
ments are provided in the supporting information section.
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